Suppr超能文献

普罗帕酮对映体口服给药后在人体中的比较药代动力学和临床药理学研究。

Comparative pharmacokinetics and clinical pharmacology of propafenone enantiomers after oral administration to man.

作者信息

Brode E, Müller-Peltzer H, Hollmann M

机构信息

Knoll AG, Dept. Biochemistry, Ludwigshafen/Rhein, FRG.

出版信息

Methods Find Exp Clin Pharmacol. 1988 Nov;10(11):717-27.

PMID:3221745
Abstract

The pharmacodynamic and pharmacokinetic behavior of (R)- and (S)-propafenone was investigated in a group of seven healthy volunteers, one of whom belonged to the phenotype of poor debrisoquine hydroxylators. Each volunteer received 250 mg of either enantiomer as a solution in randomized order with a washout period of one week in between. The pharmacodynamic evaluation comprised cardiovascular parameters (HR, PQ, QRS, QT, BP) and tolerability (self-assessment questionnaire, hematology, clinical chemistry). For pharmacokinetic purposes plasma levels of the parent compounds (R, S) and their 5-hydroxylated metabolites (5-R, 5-S) were measured. As expected, there was a small but distinct increase of PQ interval with a maximum 2 h after drug intake. No difference was observed between both enantiomers tested. In the poor hydroxylator prolongation of PQ interval was less compared to extensive metabolizers, though plasma concentrations of the unchanged drug were considerably higher. Inspection of the individual concentration time profiles in the other subjects provided additional evidence that the 5-OH-metabolite also contributes to this effect. Other ECG parameters, heart rate and blood pressure remained unaffected. Both enantiomers were well tolerated: no drug-related side effects concerning general well-being and laboratory parameters were observed. In contrast to pharmacodynamic effects (on ECG) a distinct enantioselectivity of metabolic and/or distributive processes can be observed in the group of efficient hydroxylators manifesting itself in a lower clearance for R (ratio 0.50 +/- 0.19, probability of error less than 1%), in spite of a higher terminal elimination rate constant (ratio 1.64 +/- 0.63, probability of error less than 10%). This difference cannot be accounted for by the different degrees of protein binding of the enantiomers (fu(R) = 0.076; fu(S) = 0.049). The experience obtained with one poor hydroxylator seems to indicate that enantioselectivity in terms of oral clearance Cl/F might be lost in this phenotype. The distinctly lower clearance values for the poor hydroxylator when compared to the corresponding data for efficient hydroxylators, seem to be the reflection of the lower metabolic capacity of this phenotype.

摘要

在一组7名健康志愿者中研究了(R)-和(S)-普罗帕酮的药效学和药代动力学行为,其中一名志愿者属于异喹胍羟化能力差的表型。每位志愿者随机顺序接受250mg两种对映体中的一种,以溶液形式给药,中间间隔一周的洗脱期。药效学评估包括心血管参数(心率、PQ间期、QRS波群、QT间期、血压)和耐受性(自我评估问卷、血液学、临床化学)。出于药代动力学目的,测定了母体化合物(R、S)及其5-羟基化代谢物(5-R、5-S)的血浆水平。正如预期的那样,PQ间期在服药后2小时达到最大值时有小幅但明显的增加。在测试的两种对映体之间未观察到差异。与广泛代谢者相比,异喹胍羟化能力差者的PQ间期延长较少,尽管未变化药物的血浆浓度明显更高。对其他受试者个体浓度-时间曲线的检查提供了额外证据,表明5-羟基代谢物也促成了这种效应。其他心电图参数、心率和血压未受影响。两种对映体耐受性良好:未观察到与总体健康和实验室参数相关的药物副作用。与药效学效应(对心电图)相反,在高效羟化者组中可观察到代谢和/或分布过程存在明显的对映体选择性,表现为R的清除率较低(比值0.50±0.19,误差概率小于1%),尽管终末消除速率常数较高(比值1.64±0.63,误差概率小于10%)。这种差异不能用对映体不同程度的蛋白结合来解释(fu(R)=0.076;fu(S)=0.049)。在一名异喹胍羟化能力差者身上获得的经验似乎表明,在这种表型中可能会失去口服清除率Cl/F方面的对映体选择性。与高效羟化者的相应数据相比,异喹胍羟化能力差者的清除率值明显较低,这似乎反映了该表型较低的代谢能力。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验